Targeting serotonergic terminals has been proposed as promising target for the treatment of dyskinesia (Politis et al. 2014; Di Luca et al. 2022), therefore buspirone/zolmitriptan (JM-010), agonists of 5-HT1A and 5-HT1B/D, respectively (NCT04377945, NCT03956979), and NLX-112, a 5-HT1A receptor agonist (NCT05148884), are currently investigated. The gene discussed is HTR1A; the disease is Dyskinesia.